Senior Director, Lilly Research Labs — Due Diligence,
Head Centre of Excellence, Due Diligence,
Chief Business Officer,
|Roland Pfeiffer, Ph.D.,
Head, Commercial Development Europe,
Executive Director, Diligence,
Head, External Innovation and Licensing,
Recent years have shown a rise in development across the generic and biosimilar industries, as many blockbuster products near the end of their patents. The need to expand the reach of R&D programmes has driven major new investments in co-development, strategic alliances, licensing and acquisitions, with big pharmaceutical companies scrambling to maintain their strongholds in specific therapeutic areas. This has increased the need for a robust due diligence process across all functions, as companies look to external targets as a means of supplementing pipelines and bolstering their product portfolios.
With the rising costs of drug and device reviews and the uncertainty of FDA approvals, the prospect of developing a new product from discovery onward has become a highly risky endeavour. Therefore, conducting strategic due diligence to identify and integrate potential targets at a stage of assured success, though costly, can often be an efficient approach to supplement organic business development.
Over the last four years, ExL Events’ US-based conference has provided due diligence professionals with a platform to explore innovative models and deal structures for collaborating with strategic partners, and discussed valuable strategies for conducting efficient and effective due diligence. Join your peers at the inaugural European Due Diligence Summit for Life Sciences for the opportunity to network and engage with some of the industry’s leading experts.
This conference is designed for representatives from pharmaceutical, medical device and biotechnology companies with responsibilities in the following areas:
This conference is also of interest to: